Market Overview:
The global oncology drug discovery services market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of cancer, rising demand for personalized medicines, and growing investments in oncology drug discovery research. The global oncology drug discovery services market is segmented by type into identification service, authentication service, hit-to-lead and lead optimization services, and others. The authentication service segment is expected to grow at the highest CAGR during the forecast period due to the increasing demand for quality control measures in pharmaceuticals and biotechnology companies. The global oncology drug discovery services market is also segmented by application into research institutes, pharmaceutical companies, biotechnology companies, and others.
Product Definition:
Oncology Drug Discovery Services is the process of discovering and developing new cancer drugs. This process can involve screening large numbers of potential drugs, testing them in vitro and in vivo, and eventually bringing them to market. Oncology drug discovery services are important because they can help improve the quality of life for cancer patients by providing them with new treatments options.
Identification Service:
The global identification service, its usage and growth factor in oncology drug discovery services market was valued at USD 2.5 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. Increasing R&D activities by pharmaceutical & biotechnology companies for the development of new drugs is one of the key factors driving growth globally.
Authentication Service:
The global adoption of authentication service is increasing in the oncology drug discovery services market. The major factor that can be attributed to this increase includes a rise in the incidence of cancer and demand for effective drugs.
According to WHO, it was estimated that approximately 8.2 million people died due to cancer in 2012; out of which 609,000 cases were reported among women.
Application Insights:
Based on application, the global oncology drug discovery services market is segmented into research institutes, pharmaceutical companies, biotechnology companies and others. Research institutes held the largest share of over 70% in 2017. This large share can be attributed to presence of a strong pipeline with various clinical candidates for cancer treatment as well as novel targets for cancer diagnosis.
Pharmaceutical companies are also anticipated to have lucrative growth opportunities owing to increasing R&D costs coupled with an inclination towards adoption of targeted therapies and other innovative drugs developed through collaborative research activities undertaken by leading institutions across the globe. The growing importance of these services in developing countries such as India is expected to offer numerous growth opportunities in near future.
Regional Analysis:
North America dominated the global oncology drug discovery services market in 2017. This can be attributed to the presence of a large number of CROs offering these services coupled with high R&D investment by companies operating in this region. Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to increasing government funding for cancer research and rising awareness about oncology drugs among patients & physicians. Moreover, an increase in outsourcing activities from developed regions such as North America and Europe is anticipated to drive growth across this region over the forecast period.
The Asia Pacific Oncology Drug Discovery Services Market By Country (Japan, China, India, Australia), And Segment Forecasts 2018 To 2030 China accounted for more than 30% share within Asia Pacific owing to its well-developed healthcare infrastructure along with supportive economic factors that have resulted into growing demand for clinical trials within China itself as well as from other countries around the world.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for oncology drug discovery services market. According to World Health Organization (WHO), the number of new cases of cancer is expected to rise from 14 million in 2012 to 22 million by 2030. This will create a huge demand for oncology drug discovery services, which will help in the growth of this market.
- Rising prevalence of lifestyle diseases: The rising prevalence of lifestyle diseases such as obesity and diabetes is also contributing to the growth of oncology drug discovery services market. These diseases are known to increase the risk for developing various types cancers, thereby creating a high demand for oncology drugs and related services.
- Technological advancements: The technological advancements in diagnostics and therapeutics are helping in improving the accuracy and efficiencyof oncology drug discovery process, thereby drivingthegrowthoftheoncologydrugdiscoveryservicesmarket .Forinstance,theuseofnextgenerationsequencing(NGS)technologiesinoncodiscoveryprocesshashelpedinthedetectionandcharacterizationofnewcancergenesanddrugtargets .Thiswillhelpinthesuccessfuldevelopmentofnewoncolyticdrugsandalsoimprovetheefficacyoftreatmentforcancerpatients .
Scope Of The Report
Report Attributes
Report Details
Report Title
Oncology Drug Discovery Services Market Research Report
By Type
Identification Service, Authentication Service, Hit-to-lead and Lead Optimization Services, Others
By Application
Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Others
By Companies
Charles River, Evotec, GE Healthcare Life Sciences, GenScript, Horizon Discovery, TCG Lifesciences, Zumutor, ChemPartner, Aquila BioMedical, Onconova, Vichem Chemie, GVK Biosciences, NuChem Therapeutics, Syncom, Envigo, DiverChim, Aurora, HD Biosciences, WuXi AppTec
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
197
Number of Tables & Figures
138
Customization Available
Yes, the report can be customized as per your need.
Global Oncology Drug Discovery Services Market Report Segments:
The global Oncology Drug Discovery Services market is segmented on the basis of:
Types
Identification Service, Authentication Service, Hit-to-lead and Lead Optimization Services, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Charles River
- Evotec
- GE Healthcare Life Sciences
- GenScript
- Horizon Discovery
- TCG Lifesciences
- Zumutor
- ChemPartner
- Aquila BioMedical
- Onconova
- Vichem Chemie
- GVK Biosciences
- NuChem Therapeutics
- Syncom
- Envigo
- DiverChim
- Aurora
- HD Biosciences
- WuXi AppTec
Highlights of The Oncology Drug Discovery Services Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Identification Service
- Authentication Service
- Hit-to-lead and Lead Optimization Services
- Others
- By Application:
- Research Institutes
- Pharmaceutical Companies
- Biotechnology Companies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oncology Drug Discovery Services Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oncology Drug Discovery Services is a comprehensive drug discovery and development service that helps pharmaceutical companies identify new cancer drugs. This service provides scientists with the tools and resources they need to develop novel cancer therapies, including preclinical studies, clinical trials, and product development.
Some of the major players in the oncology drug discovery services market are Charles River, Evotec, GE Healthcare Life Sciences, GenScript, Horizon Discovery, TCG Lifesciences, Zumutor, ChemPartner, Aquila BioMedical, Onconova, Vichem Chemie, GVK Biosciences, NuChem Therapeutics, Syncom, Envigo, DiverChim, Aurora, HD Biosciences, WuXi AppTec.
The oncology drug discovery services market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oncology Drug Discovery Services Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oncology Drug Discovery Services Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oncology Drug Discovery Services Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oncology Drug Discovery Services Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oncology Drug Discovery Services Market Size & Forecast, 2018-2028
4.5.1 Oncology Drug Discovery Services Market Size and Y-o-Y Growth
4.5.2 Oncology Drug Discovery Services Market Absolute $ Opportunity
Chapter 5 Global Oncology Drug Discovery Services Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Oncology Drug Discovery Services Market Size Forecast by Type
5.2.1 Identification Service
5.2.2 Authentication Service
5.2.3 Hit-to-lead and Lead Optimization Services
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Oncology Drug Discovery Services Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Oncology Drug Discovery Services Market Size Forecast by Applications
6.2.1 Research Institutes
6.2.2 Pharmaceutical Companies
6.2.3 Biotechnology Companies
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oncology Drug Discovery Services Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oncology Drug Discovery Services Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Oncology Drug Discovery Services Analysis and Forecast
9.1 Introduction
9.2 North America Oncology Drug Discovery Services Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Oncology Drug Discovery Services Market Size Forecast by Type
9.6.1 Identification Service
9.6.2 Authentication Service
9.6.3 Hit-to-lead and Lead Optimization Services
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Oncology Drug Discovery Services Market Size Forecast by Applications
9.10.1 Research Institutes
9.10.2 Pharmaceutical Companies
9.10.3 Biotechnology Companies
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Oncology Drug Discovery Services Analysis and Forecast
10.1 Introduction
10.2 Europe Oncology Drug Discovery Services Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Oncology Drug Discovery Services Market Size Forecast by Type
10.6.1 Identification Service
10.6.2 Authentication Service
10.6.3 Hit-to-lead and Lead Optimization Services
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Oncology Drug Discovery Services Market Size Forecast by Applications
10.10.1 Research Institutes
10.10.2 Pharmaceutical Companies
10.10.3 Biotechnology Companies
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Oncology Drug Discovery Services Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Oncology Drug Discovery Services Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Oncology Drug Discovery Services Market Size Forecast by Type
11.6.1 Identification Service
11.6.2 Authentication Service
11.6.3 Hit-to-lead and Lead Optimization Services
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Oncology Drug Discovery Services Market Size Forecast by Applications
11.10.1 Research Institutes
11.10.2 Pharmaceutical Companies
11.10.3 Biotechnology Companies
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Oncology Drug Discovery Services Analysis and Forecast
12.1 Introduction
12.2 Latin America Oncology Drug Discovery Services Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Oncology Drug Discovery Services Market Size Forecast by Type
12.6.1 Identification Service
12.6.2 Authentication Service
12.6.3 Hit-to-lead and Lead Optimization Services
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Oncology Drug Discovery Services Market Size Forecast by Applications
12.10.1 Research Institutes
12.10.2 Pharmaceutical Companies
12.10.3 Biotechnology Companies
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Oncology Drug Discovery Services Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Oncology Drug Discovery Services Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Oncology Drug Discovery Services Market Size Forecast by Type
13.6.1 Identification Service
13.6.2 Authentication Service
13.6.3 Hit-to-lead and Lead Optimization Services
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Oncology Drug Discovery Services Market Size Forecast by Applications
13.10.1 Research Institutes
13.10.2 Pharmaceutical Companies
13.10.3 Biotechnology Companies
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oncology Drug Discovery Services Market: Competitive Dashboard
14.2 Global Oncology Drug Discovery Services Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Charles River
14.3.2 Evotec
14.3.3 GE Healthcare Life Sciences
14.3.4 GenScript
14.3.5 Horizon Discovery
14.3.6 TCG Lifesciences
14.3.7 Zumutor
14.3.8 ChemPartner
14.3.9 Aquila BioMedical
14.3.10 Onconova
14.3.11 Vichem Chemie
14.3.12 GVK Biosciences
14.3.13 NuChem Therapeutics
14.3.14 Syncom
14.3.15 Envigo
14.3.16 DiverChim
14.3.17 Aurora
14.3.18 HD Biosciences
14.3.19 WuXi AppTec
